Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901481 · ClinicalTrials.gov registry record · NA
Empower Neuromodulation System - Pilot Study for Anxiety Treatment
A NA study, sponsored by Theranova, L.L.C..
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04901481 is a NA study that was terminated before completion, run by Theranova, L.L.C.. The registered enrollment target is 18 participants.
The verdict
NCT04901481, a NA study, was terminated before completion, sponsored by Theranova, L.L.C..
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD). This is a pilot investigation in which participants will randomized (1:1) to the active or sham treatment.
Interventions
- DEVICE Empower Neuromodulation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2023-05-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04901481
The ClinicalTrials.gov registry entry for NCT04901481 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranova, L.L.C., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Empower Neuromodulation System is the first listed.
NCT04901481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04901481 about?
NCT04901481 is a clinical study titled "Empower Neuromodulation System - Pilot Study for Anxiety Treatment". This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD). This is a pilot investigation in which participants will randomized (1:1) to the active or sham treatment.
What is the current status of trial NCT04901481?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2021-09-17. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT04901481?
The interventions under investigation include: Empower Neuromodulation System (DEVICE).
Who is sponsoring clinical trial NCT04901481?
This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.